Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCapital LeasesCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Artiva Biotherapeutics (ARTV) Cash & Equivalents (2023 - 2025)

Artiva Biotherapeutics (ARTV) has disclosed Cash & Equivalents for 3 consecutive years, with $26.7 million as the latest value for Q4 2025.

  • On a quarterly basis, Cash & Equivalents fell 33.64% to $26.7 million in Q4 2025 year-over-year; TTM through Dec 2025 was $26.7 million, a 33.64% decrease, with the full-year FY2025 number at $26.7 million, down 33.64% from a year prior.
  • Cash & Equivalents was $26.7 million for Q4 2025 at Artiva Biotherapeutics, down from $123.0 million in the prior quarter.
  • In the past five years, Cash & Equivalents ranged from a high of $123.0 million in Q3 2025 to a low of $26.7 million in Q4 2025.
  • A 3-year average of $50.9 million and a median of $48.2 million in 2024 define the central range for Cash & Equivalents.
  • Biggest YoY gain for Cash & Equivalents was 120.11% in 2025; the steepest drop was 36.93% in 2025.
  • Artiva Biotherapeutics' Cash & Equivalents stood at $53.5 million in 2023, then fell by 24.8% to $40.2 million in 2024, then plummeted by 33.64% to $26.7 million in 2025.
  • Per Business Quant, the three most recent readings for ARTV's Cash & Equivalents are $26.7 million (Q4 2025), $123.0 million (Q3 2025), and $28.5 million (Q2 2025).